ArticleScience translational medicine2017
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 64 citations in OpenAlex.
- Synergistic immunomodulatory combinations induce robust human tolerogenic dendritic cells for antigen-specific regulatory T cell generation.The Journal of pharmacology and experimental therapeutics · 2026Article
- How to manage medullary thyroid carcinoma: current treatment strategies.Drugs in context · 2026Review
- Hinge binder modification into imidazopyridine for targeting actionable mutations of RET kinase.RSC medicinal chemistry · 2025Article
- Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.Cell communication and signaling : CCS · 2024Review
- Selective RET Inhibitors (SRIs) in Cancer: A Journey from Multi-Kinase Inhibitors to the Next Generation of SRIs.Cancers · 2023Review
- Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.Nature cancer · 2023Article
- Review
- The Multikinase Inhibitor AD80 Induces Mitotic Catastrophe and Autophagy in Pancreatic Cancer Cells.Cancers · 2023Article
- RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives.Pharmacology & therapeutics · 2023Review
- A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacology.PloS one · 2023Article
- Distinctive molecular features of regenerative stem cells in the damaged male germline.Nature communications · 2022Article
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose.Journal of medicinal chemistry · 2022Article
- Targeted therapy of RET fusion-positive non-small cell lung cancer.Frontiers in oncology · 2022Review
- Review
- RET kinase inhibitors forTherapeutic advances in medical oncology · 2022Review
- MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I.Nature communications · 2021Article
- AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis.Investigational new drugs · 2021Article
- Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.Current treatment options in oncology · 2021Review
- Review
- Quantitative Proteome Data Analysis of Tandem Mass Tags Labeled Samples.Methods in molecular biology (Clifton, N.J.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 12 institutions in 7 countries.
Dennis PlenkerMolecular Pathology, Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, 50937 Cologne, Germany.ORCID 0000-0003-3895-4064
Maximilian RiedelMolecular Pathology, Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, 50937 Cologne, Germany.ORCID 0000-0002-9524-1514
Johannes BrägelmannMolecular Pathology, Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, 50937 Cologne, Germany.ORCID 0000-0002-1306-2169
Marcel A DammertMolecular Pathology, Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, 50937 Cologne, Germany.
Rakhee ChauhanStructural Biology Laboratory, Francis Crick Institute, 44 Lincoln's Inn Fields, London WC2A 3LY, UK.
Phillip P KnowlesStructural Biology Laboratory, Francis Crick Institute, 44 Lincoln's Inn Fields, London WC2A 3LY, UK.
Carina LorenzMolecular Pathology, Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, 50937 Cologne, Germany.
Marina KeulFaculty of Chemistry and Chemical Biology, TU Dortmund University, 44227 Dortmund, Germany.ORCID 0000-0003-1354-3672
Mike BührmannFaculty of Chemistry and Chemical Biology, TU Dortmund University, 44227 Dortmund, Germany.
Oliver PagelLeibniz-Institut für Analytische Wissenschaften-ISAS-e.V., Dortmund, Germany.ORCID 0000-0001-7166-6019
Verena TischlerDepartment of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany.
Andreas H ScheelInstitute of Pathology, Center of Integrated Oncology, University Hospital Cologne, 50937 Cologne, Germany.ORCID 0000-0003-0244-1646
Daniel SchütteDepartment of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany.
Yanrui SongCrown BioScience, Inc., 3375 Scott Blvd, Suite 108, Santa Clara, CA 95054, USA.ORCID 0000-0001-6717-7247
Justina StarkFaculty of Chemistry and Chemical Biology, TU Dortmund University, 44227 Dortmund, Germany.ORCID 0000-0001-5273-9884
Florian MrugallaFaculty of Chemistry and Chemical Biology, TU Dortmund University, 44227 Dortmund, Germany.
Yannic AlberFaculty of Chemistry and Chemical Biology, TU Dortmund University, 44227 Dortmund, Germany.
André RichtersFaculty of Chemistry and Chemical Biology, TU Dortmund University, 44227 Dortmund, Germany.
Julian EngelFaculty of Chemistry and Chemical Biology, TU Dortmund University, 44227 Dortmund, Germany.
Frauke LeendersNEO New Oncology GmbH, 51105 Cologne, Germany.
Johannes M HeuckmannNEO New Oncology GmbH, 51105 Cologne, Germany.ORCID 0000-0003-1714-9509
Jürgen WolfDepartment of Internal Medicine, Center for Integrated Oncology Köln Bonn, University Hospital Cologne, Cologne, 50931 Cologne, Germany.
Joachim DieboldCancer Center, Lucerne Cantonal Hospital, 6000 Lucerne, Switzerland.
Georg PallDepartment of Internal Medicine 5, University Hospital Innsbruck, Haematology/Oncology, Anichstraße 35, 6020 Innsbruck, Austria.
Martin PeiferDepartment of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany.
Maarten AertsVIB-UGent Center for Medical Biotechnology, VIB, B-9000 Ghent, Belgium.ORCID 0000-0003-0125-6721
Kris GevaertVIB-UGent Center for Medical Biotechnology, VIB, B-9000 Ghent, Belgium.
René P ZahediLeibniz-Institut für Analytische Wissenschaften-ISAS-e.V., Dortmund, Germany.
Reinhard BuettnerInstitute of Pathology, Center of Integrated Oncology, University Hospital Cologne, 50937 Cologne, Germany.
Kevan M ShokatDepartment of Cellular and Molecular Pharmacology, Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, CA 94158, USA.
Neil Q McDonaldStructural Biology Laboratory, Francis Crick Institute, 44 Lincoln's Inn Fields, London WC2A 3LY, UK.ORCID 0000-0003-0975-6325
Stefan M KastFaculty of Chemistry and Chemical Biology, TU Dortmund University, 44227 Dortmund, Germany.
Oliver GautschiCancer Center, Lucerne Cantonal Hospital, 6000 Lucerne, Switzerland.
Roman K ThomasDepartment of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany.
Martin L SosMolecular Pathology, Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, 50937 Cologne, Germany. martin.sos@uni-koeln.de.ORCID 0000-0002-2868-100X
University of Cologne · DETU Dortmund University · DEThe Francis Crick Institute · GBUniversity Hospital Cologne · DEGhent University · BEIntegrated Oncology (United States) · USLeibniz Institute for Analytical Sciences - ISAS · DEUniversity of Lucerne · CHCrown Bioscience (China) · CNGerman Cancer Research Center · DEHoward Hughes Medical Institute · USUniversity Hospital Innsbruck · AT
Funding
Selective RET Kinase and Its Mutant Inhibitors for the Treatment of Medullary Thyroid CancerR01CA197178 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI LI, HONG-YU, MCDONALD, NEIL · 2015 to 2019
$1.5MCancer Research UK FC001115Medical Research CouncilNCI NIH HHS R01 CA197178Wellcome Trust FC001115
Abstract
Oncogenic fusion events have been identified in a broad range of tumors. Among them,
Indexed as
AdenocarcinomaAdenocarcinoma of LungAnimalsCell Line, TumorCytoskeletal ProteinsDrug Resistance, NeoplasmGene RearrangementHeterocyclic Compounds, 4 or More RingsHumansImidazolesLung NeoplasmsMiceMutationNIH 3T3 CellsProtein Kinase InhibitorsProto-Oncogene Proteins c-retAD80 compoundCCDC6 protein, humanCytoskeletal ProteinsHeterocyclic Compounds, 4 or More RingsImidazolesponatinibProtein Kinase InhibitorsProto-Oncogene Proteins c-retPyridazines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.